A naukri.com initiative
Bioengineer
4d
24
Image Credit: Bioengineer
Pre-operative THP Achieves Pathological Complete Response in Two-Thirds of Early-Stage HER2-Positive, ER-Negative Breast Cancer Patients
- The CompassHER2 pCR trial investigates a less intensive neoadjuvant chemotherapy regimen using THP for early-stage HER2-positive breast cancer patients, achieving promising results.
- The study enrolled 2,175 patients, with impressive tolerability and low disease progression rates during the 12-week THP regimen.
- ER-negative, HER2-positive patients exhibited a remarkable 64% pathologic complete response (pCR) rate, highlighting the regimen's efficacy in this subgroup.
- Lower ER expression within ER-positive tumors correlated with higher pCR rates, emphasizing the importance of tumor biology in treatment response.
- The combination of trastuzumab and pertuzumab with taxane chemotherapy showed superior pCR rates, with weekly paclitaxel being favored over docetaxel.
- Advanced molecular analysis with the HER2DX pCR-score provided predictive biomarkers for treatment personalization, independent of ER status.
- Patients achieving pCR after THP could forgo post-surgery chemotherapy, minimizing toxicity while maintaining disease control.
- The study's focus on treatment de-escalation and personalized medicine reflects a shift in oncology towards tailored, less toxic therapies.
- The long-term impact of the THP regimen on recurrence-free survival is still under evaluation, with implications for future clinical guidelines.
- The study's collaborative efforts and clinical implications may influence global cancer treatment strategies, promoting effective yet minimally burdensome care.
Read Full Article
1 Like
For uninterrupted reading, download the app